Lupus & antiphospholipid syndrome

Age-Stratified 30-day Rehospitalization and Mortality and Predictors of Rehospitalization Among Patients With Systemic Lupus Erythematosus: A Medicare Cohort Study

J RheumatolPublished Retrospective cohort study

Authors' conclusion

Young adults with SLE on Medicare had very high 30-day rehospitalization at 36%. Considering socioeconomic disadvantage and comorbidities provided good prediction of rehospitalization risk, particularly in young adults.

Study context

Population
Medicare beneficiaries hospitalized in 2014 (20% national sample), with and without systemic lupus erythematosus (SLE)
Participants
1.39 million hospitalizations
Exposure
SLE vs no SLE, by age group
Outcome
Rehospitalization risk and mortality within 30 days of discharge, by age group
Follow-up
30 days after discharge
Methodological details2014 20% national Medicare sample, multivariable generalized estimating equation models
  • 2014 20% national Medicare sample
  • Multivariable generalized estimating equation models

Main finding

As reported in the abstract

30-day rehospitalization · 30 days

Young SLE

36%

Young SLE vs young peers without SLE: rehospitalization higher
40%
Young SLE vs older SLE: rehospitalization higher
85%

Observational data: associations, not effects.

Further findings

Predictors of rehospitalization in SLE

Model predictive value (C statistics)
0.67-0.77
Longer LOS and higher comorbidity risk score increased odds of rehospitalization in all age groups; specific comorbid predictors varied
  • Models incorporated neighborhood-level socioeconomic disadvantage

Original publication

Age-Stratified 30-day Rehospitalization and Mortality and Predictors of Rehospitalization Among Patients With Systemic Lupus Erythematosus: A Medicare Cohort Study. J Rheumatol. Published 15 August 2022. doi:10.3899/jrheum.220025

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.